Evidence map›Paper›PMID 38907827›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Significance of concurrent evaluation of HER2 gene amplification and p53 and Ki67 expression in gastric cancer tissues.

Su-Nan Wang, Yang-Kun Wang, Chao-Ya Zhu, Bo Jiang, Dong-Feng Ge, Ying-Ying Li

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Su-Nan Wang *Shenzhen Polytechnic, Xilihu Town, Nanshan District, Shenzhen, 518055, Guangdong, China.
Yang-Kun Wang *Department of Pathology, The Fourth People's Hospital of Longgang District, Shenzhen, 518123, China.
Chao-Ya ZhuDepartment of Pathology, Third Affiliated Hospital of Zhengzhou University, Shenzhen, 450052, China.
Bo JiangDepartment of Pathology, No. 990 Hospital of the PLA Joint Logistics Support Force, Zhumadian, 463000, China.
Dong-Feng GeDepartment of Pathology, The First Affiliated Hospital of Henan University of Science and Technology, No. 24 Jinghua Road, Jianxi District, Luoyang, 471000, China. dongfeng_gegdf@126.com.ORCID http://orcid.org/0009-0004-5431-0036
Ying-Ying LiShenzhen Polytechnic, Xilihu Town, Nanshan District, Shenzhen, 518055, Guangdong, China. liyingying0326@126.com.

Funding

Key scientific and technological research projects in Henan Province 132102310008
6 · The paper itself

Abstract

objectiveThe primary objective of this study is to explore the significance of concurrent evaluation of HER2 gene amplification and p53 and Ki67 expression in gastric cancer tissues.

methodsFluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) methodologies were used to detect HER2 gene amplification, as well as the expression levels of HER2, p53, and Ki67 proteins, across a group of 78 gastric cancer cases.

resultsThe expression rate of the HER2 protein was determined to be 43.6% (34/78), with 17.9% (14/78) categorized as HER2 protein 3 + , 14.1% (11/78) as HER2 protein 2 + , and 11.5% (9/78) as HER2 protein 1 + . Using FISH technology, the HER2 gene amplification rate was identified as 19.2% (15/78), including 3 cases of HER2 gene cluster amplification, 5 cases of large granular amplification, 4 cases of punctate amplification, and 3 cases of high polysomy. The positive rate of p53 in gastric cancer cells was 52.6% (41/78), with 62.8% (49/78) of patients exhibiting a ki67 proliferation index ≤ 30, and 37.2% (29/78) accounting for a ki67 proliferation index > 30. The expression rates of the HER2 gene, p53, and ki67 in gastric cancer tissues were significantly associated with both gastric cancer staging and lymph node metastasis (P < 0.05).

conclusionThe HER2 gene amplification rate and gene copy number exhibit a positive correlation with the expression rates of p53 and ki67. Combining these assessments can provide crucial insights into the assessment of metastatic potential, disease progression, and prognosis of gastric tumor cells. This holds paramount importance in steering the formulation of individualized treatment strategies.

Indexed as

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesGene AmplificationKi-67 AntigenStomach NeoplasmsTumor Suppressor Protein p53AdultAgedAged, 80 and overFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMaleMiddle AgedPrognosisBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesKi-67 AntigenMKI67 protein, humanTP53 protein, humanTumor Suppressor Protein p53FISHGastric tumorsHER2 geneIHCKi-67p53

Identifiers

PMID38907827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.